|
9 Companies |
|
10 Products |
|
10 Products |
|
14 Mechanisms of Action |
|
0 Trials |
|
72 News |
|
| 12» |
- Trial withdrawal: Study Evaluating The Safety And Efficacy Of PF-03654746 In Adult Subjects With Tourette's Syndrome (clinicaltrials.gov) - Apr 20, 2019
P2, N=0, Withdrawn, Sponsor: Pfizer
Terminated --> Withdrawn
- | NN1213 / Novo Nordisk, JZP150 / Jazz
Phase classification, Enrollment change, Trial completion date, Trial termination: FAAH Inhibitor Trial for Adults With Tourette Syndrome (clinicaltrials.gov) - Oct 29, 2018
P1, N=5, Terminated, Sponsor: Yale University
Terminated --> Withdrawn Phase classification: P2 --> P1 | N=10 --> 5 | Trial completion date: Dec 2017 --> Mar 2017 | Suspended --> Terminated; no more funding available
- | Trial completion, Enrollment change, Trial completion date, Trial primary completion date: Neurofeedback for Tourette Syndrome (clinicaltrials.gov) - Aug 27, 2018
P=N/A, N=21, Completed, Sponsor: Yale University
Phase classification: P2 --> P1 | N=10 --> 5 | Trial completion date: Dec 2017 --> Mar 2017 | Suspended --> Terminated; no more funding available Recruiting --> Completed | N=30 --> 21 | Trial completion date: Jun 2018 --> Dec 2017 | Trial primary completion date: Jun 2018 --> Dec 2017
- | Trial completion: Brain Stimulation for the Treatment of Tourette Syndrome (clinicaltrials.gov) - Jun 8, 2018
P=N/A, N=5, Completed, Sponsor: University of Florida
Recruiting --> Completed | N=30 --> 21 | Trial completion date: Jun 2018 --> Dec 2017 | Trial primary completion date: Jun 2018 --> Dec 2017 Active, not recruiting --> Completed
- | Phase classification: TSfMRI: Dopaminergic Effects on Cortical Function in Tourette's (Levodopa Protocol) (clinicaltrials.gov) - Feb 12, 2018
P1, N=49, Completed, Sponsor: Washington University School of Medicine
Active, not recruiting --> Completed Phase classification: P=N/A --> P1
- | Trial primary completion date: Neurofeedback for Tourette Syndrome (clinicaltrials.gov) - Sep 15, 2017
P=N/A, N=30, Recruiting, Sponsor: Yale University
Phase classification: P=N/A --> P1 Trial primary completion date: Jun 2017 --> Jun 2018
- | NN1213 / Novo Nordisk
Trial completion: Timing of Voluntary Movement in Patients With Tourette Syndrome and Chronic Tic Disorder (clinicaltrials.gov) - Jun 30, 2017
P=N/A, N=42, Completed, Sponsor: National Institute of Neurological Disorders and Stroke (NINDS)
Trial primary completion date: Jun 2017 --> Jun 2018 Active, not recruiting --> Completed
- | NN1213 / Novo Nordisk
Trial completion: Brain Dynamics Involved in Generating Tics and Controlling Voluntary Movement (clinicaltrials.gov) - Jun 30, 2017
P=N/A, N=54, Completed, Sponsor: National Institute of Neurological Disorders and Stroke (NINDS)
Active, not recruiting --> Completed Recruiting --> Completed
- | NN1213 / Novo Nordisk
Trial completion: Study of GABA-A Receptors in the Generation of Tics in Patients With Tourette's Syndrome (clinicaltrials.gov) - Jun 30, 2017
P=N/A, N=26, Completed, Sponsor: National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting --> Completed Recruiting --> Completed
- | NN1213 / Novo Nordisk
Trial completion: Study of Tics in Patients With Tourette's Syndrome and Chronic Motor Tic Disorder (clinicaltrials.gov) - Jun 30, 2017
P=N/A, N=46, Completed, Sponsor: National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting --> Completed Active, not recruiting --> Completed
- | NN1213 / Novo Nordisk
Trial completion: Evaluation and Follow-up of Individuals With Obsessive-Compulsive Disorder and Related Conditions (clinicaltrials.gov) - Jun 30, 2017
P=N/A, N=400, Completed, Sponsor: National Institute of Mental Health (NIMH)
Active, not recruiting --> Completed Recruiting --> Completed
- | Trial completion, Trial primary completion date: STIC: Pallidal Stimulation and Gilles de la Tourette Syndrome (clinicaltrials.gov) - Feb 23, 2017
P3, N=20, Completed, Sponsor: Assistance Publique - H
Recruiting --> Completed Active, not recruiting --> Completed | Trial primary completion date: Dec 2013 --> Dec 2016
- Trial completion, Enrollment change: MRI Study of Tic Remission in Tourette Syndrome (clinicaltrials.gov) - May 13, 2016
P=N/A, N=21, Completed, Sponsor: University of Utah
Active, not recruiting --> Completed | Trial primary completion date: Dec 2013 --> Dec 2016 Recruiting --> Completed | N=30 --> 21
- JZP150 / Jazz
Trial suspension: FAAH Inhibitor Trial for Adults With Tourette Syndrome (clinicaltrials.gov) - Mar 22, 2016
P2, N=10, Suspended, Sponsor: Yale University
Recruiting --> Completed | N=30 --> 21 Recruiting --> Suspended
- Trial termination: rTMSPPCGT: Repetitive Transcranial Magnetic Stimulation of the Posterior Parietal Cortex in Patients Suffering From Gilles de la Tourette Syndrome (clinicaltrials.gov) - Feb 29, 2016
P2, N=5, Terminated, Sponsor: Institut National de la Sant
Recruiting --> Suspended Completed --> Terminated; lake of efficacy
- | Ingrezza (valbenazine) / Neurocrine, Mitsubishi Tanabe
Trial completion: T-FORCE: Safety, Pharmacokinetics, and Pharmacodynamics of NBI-98854 in Children and Adolescents With Tourette Syndrome (clinicaltrials.gov) - Jan 7, 2016
P1, N=36, Completed, Sponsor: Neurocrine Biosciences
Completed --> Terminated; lake of efficacy Recruiting --> Completed
- | Trial completion: CBIT: Cognitive Behavior Therapy and Habit Reversal Training for the Treatment of Chronic Tic Disorders in Children (clinicaltrials.gov) - Dec 14, 2015
P2/3, N=120, Completed, Sponsor: Tourette Association of America
Recruiting --> Completed Active, not recruiting --> Completed
- Ingrezza (valbenazine) / Neurocrine, Mitsubishi Tanabe
Trial primary completion date: T-FORCE: Safety, Pharmacokinetics, and Pharmacodynamics of NBI-98854 in Children and Adolescents With Tourette Syndrome (clinicaltrials.gov) - Oct 6, 2015
P1, N=36, Recruiting, Sponsor: Neurocrine Biosciences
Active, not recruiting --> Completed Trial primary completion date: Jul 2015 --> Nov 2015
- Trial completion, Enrollment change: Proof-of-Concept Safety Study of CPP-109 (Vigabatrin) for Treatment Refractory Tourette's Disorder (clinicaltrials.gov) - Sep 24, 2015
P1/2, N=4, Completed, Sponsor: Barbara J. Coffey
Trial primary completion date: Jul 2015 --> Nov 2015 Recruiting --> Completed | N=10 --> 4
- Trial completion, Trial primary completion date: Neurocognitive Correlates of Behavioral Treatment for Childhood Tic Disorders (clinicaltrials.gov) - Aug 21, 2015
P=N/A, N=53, Completed, Sponsor: John Piacentini
Recruiting --> Completed | N=10 --> 4 Recruiting --> Completed | Trial primary completion date: Dec 2010 --> Dec 2011
- Trial completion, Enrollment change, Trial primary completion date, HEOR: Activity in Tourette Syndrome (clinicaltrials.gov) - Aug 11, 2015
P=N/A, N=14, Completed, Sponsor: Children's Hospital of Eastern Ontario
Recruiting --> Completed | Trial primary completion date: Dec 2010 --> Dec 2011 Recruiting --> Completed | N=20 --> 14 | Trial primary completion date: Sep 2014 --> Dec 2014
- Enrollment closed, Enrollment change, Trial primary completion date: STIC: Pallidal Stimulation and Gilles de la Tourette Syndrome (clinicaltrials.gov) - Jul 14, 2015
P3, N=20, Active, not recruiting, Sponsor: Assistance Publique - H
Recruiting --> Completed | N=20 --> 14 | Trial primary completion date: Sep 2014 --> Dec 2014 Recruiting --> Active, not recruiting | N=28 --> 20 | Trial primary completion date: Jan 2013 --> Dec 2013
- Trial completion: A Trial of Bilateral Deep Brain Stimulation to the Globus Pallidus Internum in Tourette Syndrome (clinicaltrials.gov) - Mar 19, 2015
P2, N=15, Completed, Sponsor: University College, London
Recruiting --> Active, not recruiting | N=28 --> 20 | Trial primary completion date: Jan 2013 --> Dec 2013 Active, not recruiting --> Completed
- | AZD-5213 / AstraZeneca
Trial completion: Safety, Tolerability, Pharmacokinetic, and Efficacy Study of AZD5213 in Adolescents With Tourette's Disorder (clinicaltrials.gov) - Mar 12, 2015
P2, N=29, Completed, Sponsor: AstraZeneca
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Trial completion: Developing Cognitive Training for Tourette Syndrome (clinicaltrials.gov) - Jan 15, 2015
P1, N=20, Completed, Sponsor: University of Wisconsin, Milwaukee
Active, not recruiting --> Completed Recruiting --> Completed
- Clinical: Internet-based Coaching for Young Adults With Neuropsychiatric Disorders (clinicaltrials.gov) - Dec 13, 2014
P=N/A, N=12, Completed, Sponsor: Vardalinstitutet The Swedish Institute for Health Sciences
- | AZD-5213 / AstraZeneca
Enrollment closed, Trial primary completion date: Safety, Tolerability, Pharmacokinetic, and Efficacy Study of AZD5213 in Adolescents With Tourette's Disorder (clinicaltrials.gov) - Dec 7, 2014
P2, N=29, Active, not recruiting, Sponsor: AstraZeneca
Recruiting --> Completed Recruiting --> Active, not recruiting | Trial primary completion date: Oct 2014 --> Mar 2015
- ||||||| aripiprazole / Generic mfg.
Trial completion: Safety and Tolerability of Once-daily Oral Aripiprazole in Children and Adolescents With Tourette's Disorder (clinicaltrials.gov) - Dec 7, 2014
P3, N=110, Completed, Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
Recruiting --> Active, not recruiting | Trial primary completion date: Oct 2014 --> Mar 2015 Active, not recruiting --> Completed
- Trial primary completion date: Proof-of-Concept Safety Study of CPP-109 (Vigabatrin) for Treatment Refractory Tourette's Disorder (clinicaltrials.gov) - Oct 22, 2014
P1/2, N=10, Recruiting, Sponsor: Barbara J. Coffey
Active, not recruiting --> Completed Trial primary completion date: Mar 2013 --> Mar 2015
- | Ingrezza (valbenazine) / Neurocrine, Mitsubishi Tanabe
New P1 trial: T-FORCE: Safety, Pharmacokinetics, and Pharmacodynamics of NBI-98854 in Children and Adolescents With Tourette Syndrome (clinicaltrials.gov) - Oct 4, 2014
P1, N=36, Recruiting, Sponsor: Neurocrine Biosciences
- New P2 trial: VoIP Delivered Behavior Therapy for Tourette Syndrome (clinicaltrials.gov) - Sep 28, 2014
P2, N=20, Completed, Sponsor: University of Wisconsin, Milwaukee
- Enrollment closed, Trial primary completion date: A Trial of Bilateral Deep Brain Stimulation to the Globus Pallidus Internum in Tourette Syndrome (clinicaltrials.gov) - Aug 29, 2014
P2, N=15, Active, not recruiting, Sponsor: University College, London
Trial primary completion date: Mar 2013 --> Mar 2015 Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2014 --> Nov 2014
- HEOR: Activity in Tourette Syndrome (clinicaltrials.gov) - Jun 1, 2014
P=N/A, N=20, Recruiting, Sponsor: Children's Hospital of Eastern Ontario
- pramipexole IR / Generic mfg.
Trial termination: Open-label Extension Study of Pramipexole in the Treatment of Children and Adolescents With Tourette Syndrome (clinicaltrials.gov) - May 6, 2014
P3, N=45, Terminated, Sponsor: Boehringer Ingelheim
Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2014 --> Nov 2014 Completed --> Terminated; Terminated for slow enrollment.
- JZP150 / Jazz
New P2 trial: FAAH Inhibitor Trial for Adults With Tourette Syndrome (clinicaltrials.gov) - May 6, 2014
P2, N=10, Recruiting, Sponsor: Yale University
- Trial completion date: Brain Stimulation for the Treatment of Tourette Syndrome (clinicaltrials.gov) - Apr 7, 2014
P=N/A, N=5, Active, not recruiting, Sponsor: University of Florida
Completed --> Terminated; Terminated for slow enrollment. Trial completion date: Aug 2013 --> Jun 2014
- acetylcysteine solution / Generic mfg.
Enrollment change: N-acetylcysteine (NAC) for Children With Tourette Syndrome (clinicaltrials.gov) - Mar 3, 2014
P2, N=31, Completed, Sponsor: Yale University
Trial completion date: Aug 2013 --> Jun 2014 N=40 --> 31
- Vincerinone (vatiquinone) / Sumitomo Pharma, PTC Therap
Trial completion: Open-Trial of EPI-743 for Adults With Tourette Syndrome (clinicaltrials.gov) - Mar 3, 2014
P1, N=10, Completed, Sponsor: Yale University
N=40 --> 31 Recruiting --> Completed
- acetylcysteine solution / Generic mfg.
Trial completion: N-acetylcysteine (NAC) for Children With Tourette Syndrome (clinicaltrials.gov) - Mar 3, 2014
P2, N=31, Completed, Sponsor: Yale University
Recruiting --> Completed Recruiting --> Completed
- | NN1213 / Novo Nordisk
Trial completion: Treatment of Obsessive-Compulsive Disorder (clinicaltrials.gov) - Feb 19, 2014
P4, N=74, Completed, Sponsor: University of Florida
Recruiting --> Completed Terminated --> Completed
- | AZD-5213 / AstraZeneca
Enrollment change: Safety, Tolerability, Pharmacokinetic, and Efficacy Study of AZD5213 in Adolescents With Tourette's Disorder (clinicaltrials.gov) - Dec 19, 2013
P2, N=29, Recruiting, Sponsor: AstraZeneca
Terminated --> Completed N=24 --> 29
- ||||||| aripiprazole / Generic mfg.
Trial completion: Study Evaluating the Safety and Efficacy of Fixed-dose Once-daily Oral Aripiprazole in Children and Adolescents With Tourette's Disorder (clinicaltrials.gov) - Sep 17, 2013
P3, N=133, Completed, Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
N=24 --> 29 Active, not recruiting --> Completed
- | AZD-5213 / AstraZeneca
Enrollment open: Safety, Tolerability, Pharmacokinetic, and Efficacy Study of AZD5213 in Adolescents With Tourette's Disorder (clinicaltrials.gov) - Sep 12, 2013
P2, N=29, Recruiting, Sponsor: AstraZeneca
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- | AZD-5213 / AstraZeneca
New P2 trial: Safety, Tolerability, Pharmacokinetic, and Efficacy Study of AZD5213 in Adolescents With Tourette's Disorder (clinicaltrials.gov) - Jul 18, 2013
P2, N=29, Recruiting, Sponsor: AstraZeneca
- ||||||| aripiprazole / Generic mfg.
Trial completion: Aripiprazole in Children and Adolescents With Chronic Tic Disorder or Tourette's Disorder (clinicaltrials.gov) - Jun 18, 2013
P3, N=61, Completed, Sponsor: Korea Otsuka Pharmaceutical Co.,Ltd.
Not yet recruiting --> Recruiting Recruiting --> Completed
- Enrollment change: Repetitive Transcranial Magnetic Stimulation to Reduce Tics (clinicaltrials.gov) - Apr 21, 2013
P1, N=12, Completed, Sponsor: Children's Hospital Medical Center, Cincinnati
Recruiting --> Completed N=24 --> 12
- Trial completion: Repetitive Transcranial Magnetic Stimulation to Reduce Tics (clinicaltrials.gov) - Apr 21, 2013
P1, N=12, Completed, Sponsor: Children's Hospital Medical Center, Cincinnati
N=24 --> 12 Recruiting --> Completed
- ||||| aripiprazole / Generic mfg.
Enrollment closed: Safety and Tolerability of Once-daily Oral Aripiprazole in Children and Adolescents With Tourette's Disorder (clinicaltrials.gov) - Apr 2, 2013
P3, N=111, Active, not recruiting, Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
Recruiting --> Completed Not yet recruiting --> Active, not recruiting
- Enrollment open: Proof-of-Concept Safety Study of CPP-109 (Vigabatrin) for Treatment Refractory Tourette's Disorder (clinicaltrials.gov) - Jan 2, 2013
P1/2, N=10, Recruiting, Sponsor: Barbara J. Coffey
Not yet recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- |||||||||| aripiprazole / Generic mfg.
New P3 trial: Safety and Tolerability of Once-daily Oral Aripiprazole in Children and Adolescents With Tourette's Disorder (clinicaltrials.gov) - Nov 14, 2012
P3, N=111, Active, not recruiting, Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.